Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Patent
1994-05-02
1998-05-26
Fitzgerald, David L.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
424 851, 424 852, 424 854, 4241521, 424 9371, 4241721, 4241741, 4353723, A61K 4505, A61K 39395, A61K 3820, A61K 3821
Patent
active
057560978
ABSTRACT:
This invention relates to processes and compositions for the immunotherapeutic treatment of cancer and non-malignant tumors. More particularly, this invention relates to processes and compositions for enhancing the body's immune response by increasing the cytotoxic activity of cells which mediate antibody dependent cellular cytotoxicity. Cells which are characterized by increased cytotoxic activity, as a result of the process of this invention, are useful in methods and compositions for the treatment of various types of cancer and non-malignant tumors.
REFERENCES:
patent: 3719182 (1973-03-01), Rose
patent: 3964467 (1976-06-01), Rose
patent: 4152208 (1979-05-01), Quirgis
patent: 4390623 (1983-06-01), Fabricius et al.
patent: 4464355 (1984-08-01), Fabricius et al.
patent: 4596774 (1986-06-01), Chang et al.
patent: 4690915 (1987-09-01), Rosenberg
patent: 4844893 (1989-07-01), Honsik et al.
patent: 5308626 (1994-05-01), Landucci et al.
Baines, M.G., et al, "Involvement of Transferrin and Transferrin Receptors in Human Natural Killer Effector: Target Interaction," Immunol. Lett.,
Brunswick, M. and Lake, P., "Obligatory Role of Gamma Interferon in T Cell Replacing Factor-Dependent, Antigen-Specific Murine B Cell Responses," J. Exp. Med., 161:953-971 (1985).
Burns, G.F., et al, "In Vitro Generation of Human Activated Lymphocyte Killer Cells: Separate Precursors and Modes of Generation of NK-like Cells and `Anomalous` Killer Cells," J. Immunol., 133(3):1656-1663 (1984).
Chang, A.E., et al, "Systemic Administration of Recombinant Human Interleukin-2 in Mice," J. Biol. Response Modifiers, 3(5):561-571 (1984).
Cheever, M.A., et al, "Potential for Specific Cancer Therapy with Immune T Lymphocytes," J. Biol. Response Modifiers, 3(2):113-127 (1984).
Cohen, B.L., et al., "Suppression by Alpha-Fetoprotein of Murine Natural Killer Cell Activity Stimulated in Vitro and in Vivo by Interferon and 533-534, abst. No. 146971e (1986)!.
Diener, E., et al, "Specific Immunosuppression by Immunotoxins Containing Daunomycin," Science, 231:148-150 (1986).
Engers, H.D., et al, "Functional Activity In Vivo of Effector T Cell Populations II. Anti-Tumor Activity Exhibited B Syngeneic Anti-MoMULV-Specific Cytolytic T Cell Clones," J. Immunol., 133(3):1664-1670 (1984).
Fabricius, H.A. and Stahn, R., "Human Primary T-Cell Lines in Lectin-free Media," Immunobiol., 156:364-371 (1979).
Fridman, W.H., et al, "Interferon Enhances the Expression of Fe.tau. Receptors," J. Immunol., 124(5):2436-2441 (1980).
Fukui, H. and Reynolds, C.W.,"Characterization of Rat Large Granular Lymphocytes in NK and ADCC and Their Modulation by Biological Response Modifiers," Proc. 14th International Congress of Chemotherapy, Kyoto, Japan, Jun. 23-28, 1985. In: Recent Advances in Chemotherapy Anti Cancer Section 2, Ed. Joji Ischigami, University of Tokyo Press: pp. 971-972 (1985).
Fujiwara, H., et al, "The Role of Tumor-Specific Lyt-1.sup.+ 2.sup.- T Cells in Eradicating Tumor Cells In Vivo," J. Immunol., 133(3):1671-1676 (1984).
Fuson, E.W., et al, "Antibody-Dependent Cell-Mediated Cytotoxicity by Human Lymphocytes," J. Immunol., 120(5):1726-1732 (1978).
Gore, M.E., et al, "Antibody-Dependent-Cellular-Cytotoxicity Against Cultured Human Breast Cancer Cells Mediated by Human Effector Cells Using Monoclonal and Polyclonal Antibodies," Br. J. Cancer, 48:877-879 (1983).
Greenberg, P.D. and Cheever, M.A., "Treatment of Disseminated Leukemia with Cyclophosphamide and Immune Cells: Tumor Immunity Reflects Long-Term Persistence of Tumor-Specific Donor T Cells," J. Immunol.,
Greenberg, P.D., et al, "Therapy of Disseminated Murine Leukemia with Cyclophosphamide and Immune Lyt-1.sup.+ 2.sup.- T Cells," J. Exp. Med.,
Greiner, J.W., "Enhanced Expression of Surface Tumor-associated Antigens on Human Breast and Colon Tumor Cells after Recombinant Human Leukocyte .alpha.-Interferon Treatment," Cancer Res., 44:3208-3214 (1987).
Grimm, E.A., et al, "Lymphokine-Activated Killer Cell Phenomenon: Lysis of Natural Killer-resistant Fresh Solid Tumor Cells by Interleukin-2 Activated Autologous Human Peripheral Blood Lymphocytes," J.Exp. Med., 155:1823-1841 (1982).
Guyre, P.M., et al, "Recombinant Immune Interferon Increases Immunoglobulin G Fc Receptors on Cultured Human Mononuclear Phagocytes," J. Clin. Invest., 72:393-397 (1983).
Hefeneider, S.H., et al, "In Vivo Interleukin 2 Administration Augments the Generation of Alloreactive Cytolytic T Lymphocytes and Resident Natural Killer Cells," J. Immunol., 130(1):222-227 (1983).
Imai, K., et al, "Differential Effect of Interferon on the Expression of Tumor-Associated Antigens and Histopcompatibility Antigens on Human Melanoma Cells: Relationship to Susceptibility to Immune Lysis Mediated by Monoclonal Antibodies," J. Immunol., 127(2):505-508 (1981).
Imai, K., et al, "ADCC of Cultured Human Melanoma Cells: Analysis with Monoclonal Antibodies to Human Melanoma-associated Antigens," Scand. J. Immunol., 14:369-377 (1981).
Issekutz. T.B., "Effects of Six Different Cytokines on Lymphocyte Adherence to Microvascular Endothelium and In Vivo Lymphocyte Migration in the Rat," J. Immunol., 144(6):2140-2146 (1990).
Jones, J.F. and Segal, D.M., "Antibody-Dependent Cell-Mediated Cytolysis (ADCC) with Antibody-Coated Effectors: New Methods for Enhancing Antibody Binding and Cytolysis," J. Immunol., 125(2):926-933 (1980).
Karpovsky, B., et al, "Production of Target-Specific Effector Cells Using Hetero-Cross-Linked Aggregates Containing Anti-Target Cell and Anti-Fe.tau. Receptor Antibodies," J. Exp. Med., 160:1686-1701 (1984).
Kedar, E., et al, "Immunotherapy of Murine and Human Tumors in Mice with Lymphokines and Interleukin-2-Propagated Lymphocytes," J. Biol. Response Modifiers, 3:517-526 (1984).
Kimber, I., et al, "Influence of Lectin-Free Interleukin-2 on Natural and Antibody-Dependent Cellular Cytotoxicity," J. Clin. Lab. Immunol., 15:77-84 (1984).
Kosugi, A., et al., "Tumor-Specific Immunotherapy: Active Immunotherapy by Augmenting the Induction of Tumor-Specific Effector T Cells through a T-T Cell Interaction Mechanism," Jpn. J. Cancer Chemotherapy, 11(8):1527-1535 (1984).
Lanier, L.L, et al, "Recombinant Interleukin 2 Enhanced Natural Killer Cell-Mediated Cytotoxicity in Human Lymphocyte Subpopulations Expressing the Leu 7 and Leu 11 Antigens," J. Immunol., 134(2):794-801 (1985).
Lotze, M.T., et al, "Lysis of Fresh and Cultured Autologous Tumor by Human Lymphocytes Cultured in T-Cell Growth Factor," Cancer Res., 41:4420-4425 (1981).
Lotze, M.T., et al, "Systemic Administration of Interleukin-2 in Humans," J. Biol. Response Modifiers, 3(5):475-482 (1984).
Lowenthal, J.W., et al, "Antigenic Stimulation Regulates the Expression of Il 2 Receptors in a Cytolyitc T Lymphocyte Clone," J. Immunol., 134(2):931-939 (1985).
Mazumder, A., et al, "Lysis of Fresh Human Solid Tumors by Autologous Lymphocytes Activated In Vitro with Lectins," Cancer Res.,42:913-918 (1982).
Mazumder, A., et al , "Phase I Study of the Adoptive Immunotherapy of Human Cancer with Lectin Activated Autologous Mononuclear Cells," Cancer, 53:896-905 (1984).
Merluzzi, V.J. and Last-Barney, K., "Expansion of Murine Cytotoxic Precursors In Vitro and In Vivo by Purified Interleukin-2," J. Biol. Response Modifiers, 3(5):468-474 (1984).
Moretta, L., et al, "Surface Markers of Cloned Human T Cells with Various Cytolytic Activities," J. Exp. Med., 154:569-579 (1981).
Mule, J.J., et al, "Active Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2," Science, 225:1487-1489 (1984).
Nair, M.P.N. and Schwartz, S.A., "Suppression of Human Natural and Antibody-Dependent Cytotoxicity by Soluble Factors from Unstimulated Normal Lymphocytes," J. Immunol., 129(6):2511-2518 (1982).
Nio, Y., et al, "Augmentation of Cytotoxicity of Lymphokine Activated Killer Cells on Ovarian Tumor Cells by Various Biological Response Modifiers," AntiCancer Res., 10:441-446 (1990).
Phillips, J.H. and Lanier, L.L., "A Model for the Differentiation of Human Natural Killer Cells: Studies on the In Vitro Activation of Leu-11+ Granular Lymphocytes with a Natural K
Landucci Gary R.
Mariani Toni N.
LandOfFree
Lymphokine activated effector cells for antibody-dependent cellu does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Lymphokine activated effector cells for antibody-dependent cellu, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Lymphokine activated effector cells for antibody-dependent cellu will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1957287